Journal
PHARMACEUTICAL RESEARCH
Volume 26, Issue 4, Pages 836-845Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-008-9782-1
Keywords
cell-penetrating peptide; doxorubicin; drug delivery systems; drug resistance; maurocalcine
Funding
- Inserm
- Life Sciences Division innovation program of the Commissariat a l'Energie Atomique
- Delegation Generale de la Recherche Scientifique et Technique (Tunisia)
- University of Monastir and University Joseph Fourier
Ask authors/readers for more resources
The aim of this study is to overcome tumour cell resistance that generally develops after administration of commonly used anti-cancer drugs, such as doxorubicin. Recently, cell penetrating peptides have been used for their ability to deliver non-permeant compounds into cells. One such cell penetrating peptide, maurocalcine, has been isolated from the venom of a Tunisian scorpion. Herein, we report the effects of doxorubicin covalently coupled to an analogue of maurocalcine on drug-sensitive or drug-resistant cell lines MCF7 and MDA-MB 231. We demonstrated the in vitro anti-tumoral efficacy of the doxorubicin maurocalcine conjugate. On a doxorubicin-sensitive cancer cell line, the maurocalcine-conjugated form appears slightly less efficient than doxorubicin itself. On the contrary, on a doxorubicin-resistant cancer cell line, doxorubicin coupling allows to overcome the drug resistance. This strategy can be generalized to other cell penetrating peptides since Tat and penetratin show similar effects. We conclude that coupling anti-tumoral drugs to cell penetrating peptides represent a valuable strategy to overcome drug resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available